{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:27:32Z","timestamp":1792783652551,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Collaborative Research and Development"},{"DOI":"10.13039\/501100000038","name":"NSERC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Replicor Inc."}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.antiviral.2019.02.009","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T11:23:01Z","timestamp":1550056981000},"page":"97-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"special_numbering":"C","title":["Inhibition of HBsAg secretion by nucleic acid polymers in HepG2.2.15\u202fcells"],"prefix":"10.1016","volume":"164","author":[{"given":"Matthieu","family":"Blanchet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vigigah","family":"Sinnathamby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Vaillant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Labont\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2019.02.009_bib1","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/0167-7799(96)10053-6","article-title":"Antisense oligonucleotides: towards clinical trials","volume":"14","author":"Agrawal","year":"1996","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.antiviral.2019.02.009_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156667","article-title":"Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection","volume":"11","author":"Al-Mahtab","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.02.009_bib3","series-title":"Toll-Like Receptors (TLRs) and Innate Immunity","author":"Bauer","year":"2008"},{"key":"10.1016\/j.antiviral.2019.02.009_bib4","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","article-title":"Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial","volume":"2","author":"Bazinet","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2019.02.009_bib5","doi-asserted-by":"crossref","first-page":"S517","DOI":"10.1016\/S0168-8278(18)31283-2","article-title":"Updated follow-up analysis in the REP 401 protocol: treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated interferon alfa-2a","volume":"68","author":"Bazinet","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2019.02.009_bib6","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01416-17","article-title":"Nucleic acid polymers are active against hepatitis delta virus infection in vitro","volume":"92","author":"Beilstein","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.02.009_bib7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.antiviral.2016.02.006","article-title":"Statins can exert dual, concentration dependent effects on HCV entry in vitro","volume":"128","author":"Blanchet","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.02.009_bib8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/1743-422X-6-214","article-title":"Amphipathic DNA polymers exhibit antiviral activity against systemic murine cytomegalovirus infection","volume":"6","author":"Cardin","year":"2009","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2019.02.009_bib9","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/jnci\/dji252","article-title":"A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer","volume":"97","author":"Chi","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.antiviral.2019.02.009_bib10","doi-asserted-by":"crossref","first-page":"13483","DOI":"10.1128\/JVI.79.21.13483-13496.2005","article-title":"Reduced secretion of virions and hepatitis B virus (HBV) surface antigen of a naturally occurring HBV variant correlates with the accumulation of the small S envelope protein in the endoplasmic reticulum and Golgi apparatus","volume":"79","author":"Chua","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.02.009_bib11","first-page":"347","article-title":"Antisense oligonucleotides: basic concepts and mechanisms","volume":"1","author":"Dias","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.antiviral.2019.02.009_bib12","doi-asserted-by":"crossref","first-page":"9242","DOI":"10.1073\/pnas.89.19.9242","article-title":"Single-stranded nucleic acid helical secondary structure stabilized by ionic bonds: d(A(+)-G)10","volume":"89","author":"Dolinnaya","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2019.02.009_bib13","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s12072-016-9738-1","article-title":"HBsAg loss in chronic hepatitis B: pointers to the benefits of curative therapy","volume":"10","author":"Dusheiko","year":"2016","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.antiviral.2019.02.009_bib14","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2019.02.009_bib15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.antiviral.2019.02.009_bib16","doi-asserted-by":"crossref","first-page":"12650","DOI":"10.1021\/bi000746+","article-title":"Parallel self-associated structures formed by T,C-rich sequences at acidic pH","volume":"39","author":"Geinguenaud","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.antiviral.2019.02.009_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179697","article-title":"Inhibition of hepatitis B viral entry by nucleic acid polymers in HepaRG cells and primary human hepatocytes","volume":"12","author":"Guillot","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.02.009_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010682","article-title":"A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo","volume":"5","author":"Gupta","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.02.009_bib19","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1083\/jcb.118.6.1305","article-title":"Hepatitis B surface antigen assembles in a post-ER, pre-Golgi compartment","volume":"118","author":"Huovila","year":"1992","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.antiviral.2019.02.009_bib20","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1021\/bi961528c","article-title":"Spectroscopic evidence for the formation of four-stranded solution structure of oligodeoxycytidine phosphorothioate","volume":"36","author":"Kanehara","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.antiviral.2019.02.009_bib21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Kariko","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.antiviral.2019.02.009_bib22","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/intimm\/dxp017","article-title":"The roles of TLRs, RLRs and NLRs in pathogen recognition","volume":"21","author":"Kawai","year":"2009","journal-title":"Int. Immunol."},{"key":"10.1016\/j.antiviral.2019.02.009_bib23","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1093\/nar\/gkr089","article-title":"Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes","volume":"39","author":"Koller","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2019.02.009_bib24","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1146\/annurev.immunol.20.100301.064842","article-title":"CpG motifs in bacterial DNA and their immune effects","volume":"20","author":"Krieg","year":"2002","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.antiviral.2019.02.009_bib25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2016.08.022","article-title":"Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B","volume":"66","author":"Lai","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2019.02.009_bib26","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1038\/ctg.2017.51","article-title":"Seven-year treatment outcome of entecavir in a real-world cohort: effects on clinical parameters, HBsAg and HBcrAg levels","volume":"8","author":"Lam","year":"2017","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.antiviral.2019.02.009_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0034169","article-title":"Activation of ERAD pathway by human hepatitis B virus modulates viral and subviral particle production","volume":"7","author":"Lazar","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.02.009_bib28","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/nar\/22.9.1600","article-title":"Intramolecular folding of a fragment of the cytosine-rich strand of telomeric DNA into an i-motif","volume":"22","author":"Leroy","year":"1994","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2019.02.009_bib29","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.virol.2007.06.048","article-title":"The degradation pathway for the HBV envelope proteins involves proteolysis prior to degradation via the cytosolic proteasome","volume":"369","author":"Liu","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.02.009_bib30","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1093\/nar\/22.22.4634","article-title":"Evidence for intramolecularly folded i-DNA structures in biologically relevant CCC-repeat sequences","volume":"22","author":"Manzini","year":"1994","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2019.02.009_bib31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2019.02.009_bib32","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1007\/s10620-015-4027-8","article-title":"Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B: a 3-year, prospective, real-world study in France","volume":"61","author":"Marcellin","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.antiviral.2019.02.009_bib33","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1053\/j.gastro.2009.04.048","article-title":"Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry","volume":"137","author":"Matsumura","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2019.02.009_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140909","article-title":"Therapeutic Antiviral Effect of the Nucleic Acid Polymer REP 2055 against Persistent Duck Hepatitis B Virus Infection","volume":"10","author":"Noordeen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.02.009_bib35","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1128\/AAC.01003-13","article-title":"Nucleic acid polymers inhibit duck hepatitis B virus infection in vitro","volume":"57","author":"Noordeen","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.02.009_bib36","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1128\/AAC.01005-13","article-title":"Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo","volume":"57","author":"Noordeen","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.02.009_bib37","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1128\/JVI.02741-06","article-title":"Hepatitis B virus subviral envelope particle morphogenesis and intracellular trafficking","volume":"81","author":"Patient","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.02.009_bib38","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","author":"Polaris Observatory","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2019.02.009_bib39","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1002\/hep.29737","article-title":"Nucleic acid polymer REP 2139 and nucleos(T)ide analogues act synergistically against chronic hepadnaviral infection in vivo in Pekin ducks","volume":"67","author":"Quinet","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2019.02.009_bib40","doi-asserted-by":"crossref","first-page":"43838","DOI":"10.1038\/srep43838","article-title":"Nucleic acid-based polymers effective against hepatitis B Virus infection in patients don't harbor immunostimulatory properties in primary isolated liver cells","volume":"7","author":"Real","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2019.02.009_bib41","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.it.2015.02.001","article-title":"RNA degradation in antiviral immunity and autoimmunity","volume":"36","author":"Rigby","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.antiviral.2019.02.009_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2017.04.019","article-title":"Nucleic acid polymers with accelerated plasma and tissue clearance for chronic hepatitis B therapy","volume":"8","author":"Roehl","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.antiviral.2019.02.009_bib43","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1128\/JVI.01902-09","article-title":"Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction","volume":"84","author":"Schulze","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.02.009_bib44","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2019.02.009_bib45","doi-asserted-by":"crossref","first-page":"5048","DOI":"10.1158\/1078-0432.CCR-03-0701","article-title":"A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer","volume":"10","author":"Tolcher","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.antiviral.2019.02.009_bib46","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.antiviral.2016.07.004","article-title":"Nucleic acid polymers: broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection","volume":"133","author":"Vaillant","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.02.009_bib47","doi-asserted-by":"crossref","DOI":"10.1021\/acsinfecdis.8b00156","article-title":"REP 2139: antiviral mechanisms and applications in achieving functional control of HBV and HDV infection","author":"Vaillant","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.02.009_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2016.02.002","article-title":"Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen-positive chronic hepatitis B patients","volume":"22","author":"van Campenhout","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.antiviral.2019.02.009_bib49","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"Werle-Lapostolle","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2019.02.009_bib50","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1093\/nar\/gkv060","article-title":"High-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotides","volume":"43","author":"Yang","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2019.02.009_bib51","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/aps.2013.175","article-title":"Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation","volume":"35","author":"Yang","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.antiviral.2019.02.009_bib52","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3748\/wjg.v11.i4.508","article-title":"Detection of hepatitis B virus DNA by real-time PCR using TaqMan-MGB probe technology","volume":"11","author":"Zhao","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2019.02.009_bib53","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/ni.1979","article-title":"Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5","volume":"12","author":"Zust","year":"2011","journal-title":"Nat. Immunol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218307551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218307551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T16:51:30Z","timestamp":1662915090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218307551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":53,"alternative-id":["S0166354218307551"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.02.009","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of HBsAg secretion by nucleic acid polymers in HepG2.2.15\u202fcells","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}